With its stock up by around 1,230% since February of 2020, Novavax (NASDAQ: NVAX) brought a whole new sizzle to the market during the race to develop a coronavirus vaccine. Since the start of the pandemic, the company has grown like a weed -- and frequently also wilted like a houseplant left too long in direct sunlight. This year, the stock is down by nearly 40%.
Can the company's global sales of coronavirus vaccine restore the market's confidence in its ability to make more profits tomorrow than it did today? Let's investigate one tailwind and one headwind for this stock, so we can get a better idea about how it's likely to perform in 2022.
Image source: Getty Images.
For further details see:
1 Green Flag For Novavax in 2022, and 1 Red Flag